"The trial's rigorous methodology and the promising results, particularly in high-risk groups with liver metastasis, offer a beacon of hope for a patient population with limited treatment options. "
"There was a 57% reduction in risk of progression or death in patients with liver metastasis with cabo/atezo, [and] a 43% reduction in risk of progression or death in patients who received prior docetaxel chemotherapy in the hormone-sensitive setting. Even in patients with bone metastasis, there was a 33% reduction in risk of progression or death."
AR-V7 - CTC's - Risk of Death
Prazosin vs. Doxazosin for Prostate Cancer Inhibition
